Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evaluating Hyperpolarized and Proton Brain Metabolism in Patients With Glioblastoma
NCT04019002Phase 1Terminated
- Start
- Nov 2019
- Primary completion
- Sep 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of Hyperpolarized Pyruvate (13C) Injection + Gadolinium in glioblastoma (GBM) (3 arms). Primary endpoints: Number of Treatment Emergent Adverse Events at 4 months, Number of Dose-Limiting Toxicities at 4 months and 2 more. Started Nov 2019; status: terminated.
02
Drugs
Hyperpolarized Pyruvate (13C) Injection + Gadolinium
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT04019002.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04019002.